Italian startup CellPly secured a 2 million euros round of financing from Italian Angels for Growth (IAG), Zernike Meta Ventures (through its Ingenium Emilia Romagna II Fund) and from Atlante Seed (Intesa Sanpaolo group), MF-Milano Finanza writes today.
New equity will help the company to finalize its diagnostic platform. Based in Bologna and led by ceo and founder Massimo Bocchi, Cellply is a biotechnology company committed to the development of solutions for personalized cancer therapy based on diagnostic platforms that define cell response to drug treatments.
The micro-technologies developed at Cellply enable the ex-vivo measurement of the response of each cell in the sample to diverse drug treatments while maintaining tumor microenvironment characteristics. The technology supports the automation of biological protocols and allows the integration of sample preparation and functional analysis procedures.